The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InPalisade Bio (Nasdaq: PALI) announced positive topline results from its Phase 1b study of PALI-2108, an oral PDE4 inhibitor targeting Crohn's disease. The study demonstrated significant clinical activity, with the drug showing a 47.5% reduction in the SES-CD score, a key indicator of endoscopic improvement. Notably, 40% of the participating patients achieved both endoscopic response and remission within just two weeks of treatment. The trial successfully met its primary endpoints for safety and tolerability, providing a strong foundation for further clinical development. Following these favorable results, the company plans to advance PALI-2108 into Phase 2 clinical trials for patients with moderate to severe Crohn's disease. This development marks a significant milestone for the biotech firm as it seeks to address unmet needs in fibrostenotic Crohn's disease.